Skip to content
Parakho

Sanjivani Paranteral Ltd

BSE 531569sanjivani.co.in

Q1 FY27, unaudited

Revenue
₹19.46 Cr
Profit after tax
₹2.30 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations19.46+8.75%64.76
Other income0.15+320.06%1.24
Total income19.61+9.38%66.00
Employee benefit expense1.75+15.39%6.33
Finance costs0.18−17.75%0.54
Depreciation & amortisation0.31+89.06%0.86
Total expenses16.55+5.89%56.77
Profit before tax3.06+33.03%9.23
Tax expense0.77+34.23%2.31
Profit after tax2.30+32.64%6.92
Total comprehensive income2.30+32.64%6.92
Earnings per share
Earnings per share, basic₹1.87₹5.67
Earnings per share, diluted₹1.87₹5.67

Q1 FY27 — unaudited, from the company’s filing with BSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with BSE. Source

FY26 — from the company’s filing with BSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q4 FY26

Sanjivani Paranteral reported a year-on-year decline in Q4 FY26 revenue after Iran-related geopolitical disruptions halted Middle East export shipments during March 2026, while raw material and packing input costs also rose during the quarter. Standalone Q4 revenue was INR 105.1 million with EBITDA margin of 14.7%, and consolidated revenue was INR 132.1 million with EBITDA margin of 15.74%. Management said alternate logistics routes have been established and expects export recovery in Q1 FY27, alongside continued ramp-up of the Pune IV fluids facility and the Prague nutraceutical joint venture.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 43 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 28 Sept 2026.